Biohaven (BHVN) shares surged after the company's troriluzole drug showed significant slowed progression of spinocerebellar ataxia, a rare neurological disease. George Tsilis shares how the promising results can mark the beginning of a long road to success for Biohaven.
Market On Close
23 Sep 2024
SHARE
Current show
Mon—Fri at 3:30 pm — 4:00 pm
Market Overtime